Product Description
Ciraparantag, an anticoagulant reversal agent, binds noncovalently to heparin, low-molecular-weight heparin, and DOACs. (Sourced from: https://ashpublications.org/blood/article/137/1/115/474177/Ciraparantag-an-anticoagulant-reversal-drug)
Mechanisms of Action: Heparin Agonist, DT Inhibitor, FXa Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Amag Pharma
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Healthy Volunteers
Phase 1: Healthy Volunteers|Other
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT02205905 |
PER977-01-004 | P1 |
Completed |
Healthy Volunteers |
2014-08-01 |
2020-05-19 |
Primary Endpoints|Treatments |
|
NCT01826266 |
PER977-P1 | P1 |
Completed |
Other |
2013-12-01 |
2020-05-19 |
Primary Endpoints|Treatments |
|
NCT04593784 |
AMAG-977-213 | P2 |
Terminated |
Healthy Volunteers |
2023-08-26 |
12% |
2025-04-09 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
NCT03172910 |
PER977-02-012 | P2 |
Completed |
Healthy Volunteers |
2019-11-12 |
31% |
2020-09-16 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
NCT03288454 |
PER977-02-011 | P2 |
Completed |
Healthy Volunteers |
2019-08-05 |
30% |
2020-09-09 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status |
NCT02206087 |
PER977-01-002 | P2 |
Completed |
Healthy Volunteers |
2016-03-01 |
2020-05-19 |
Primary Endpoints|Treatments |
|
NCT02207257 |
PER977-02-001 | P2 |
Completed |
Healthy Volunteers |
2015-09-01 |
2020-05-19 |
Primary Endpoints|Treatments |
|
NCT02206100 |
PER977 | P2 |
Completed |
Healthy Volunteers |
2014-08-01 |
2020-05-19 |
Primary Endpoints|Treatments |